• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Allurion Technologies Inc.

    10/24/24 5:19:39 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care
    Get the next $ALUR alert in real time by email
    SC 13D/A 1 p24-3055sc13da.htm ALLURION TECHNOLOGIES INC.

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D/A
    (Amendment No. 3)

    Under the Securities Exchange Act of 1934

    ALLURION TECHNOLOGIES, INC.
    (Name of Issuer)

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

    02008G102
    (CUSIP Number)

    RTW Investments, LP
    Attn: Roderick Wong, M.D.
    40 10th Avenue, Floor 7
    New York, New York 10014
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    October 22, 2024
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 02008G10213D/APage 2 of 5 Pages

    1

    NAME OF REPORTING PERSON

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    3,666,589 (including 479,196 Shares issuable upon conversion of the Notes (as defined in Item 4 of Amendment No. 1) and 239,842 Shares issuable upon exercise of Public Warrants (as defined in Item 4 of Amendment No. 2))*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    3,666,589 (including 479,196 Shares issuable upon conversion of the Notes and 239,842 Shares issuable upon exercise of Public Warrants)*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    3,666,589 (including 479,196 Shares issuable upon conversion of the Notes and 239,842 Shares issuable upon exercise of Public Warrants)*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    5.7%*

    14

    TYPE OF REPORTING PERSON

    PN, IA

           

     * Percentage based upon 64,338,421 Shares which is the difference obtained by subtracting (x) the 749,998 Shares surrendered to the Company as reported herein in Item 4 from (x) the 64,369,381 Shares reported to be outstanding as of September 23, 2024, as disclosed in the Company's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on October 7, 2024, and assumes the conversion of the Notes up to the Conversion Cap (as defined in Item 4 of Amendment No. 1) and the exercise of the Public Warrants and no conversion of the Series A Preferred Stock or exercise of the Private Warrants.

    The Public Warrants held by the RTW Funds are subject to a Blocker (as defined in Item 4 of Amendment No. 2), which is currently set at 4.99% and can be increased to 9.99% upon 61 days’ prior notice and accordingly, the Reporting Persons have included the Shares issuable upon exercise of Public Warrants as if the Blocker was set to 9.99%.

     

     

    CUSIP No. 02008G10213D/APage 3 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    Roderick Wong, M.D.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    3,666,589 (including 479,196 Shares issuable upon conversion of the Notes and 239,842 Shares issuable upon exercise of Public Warrants)*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    3,666,589 (including 479,196 Shares issuable upon conversion of the Notes and 239,842 Shares issuable upon exercise of Public Warrants)*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    3,666,589 (including 479,196 Shares issuable upon conversion of the Notes and 239,842 Shares issuable upon exercise of Public Warrants)*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    5.7%*

    14

    TYPE OF REPORTING PERSON

    IN, HC

             

    * Percentage based upon 64,338,421 Shares which is the difference obtained by subtracting (x) the 749,998 Shares surrendered to the Company as reported herein in Item 4 from (x) the 64,369,381 Shares reported to be outstanding as of September 23, 2024, as disclosed in the Company's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on October 7, 2024, and assumes the conversion of the Notes up to the Conversion Cap and the exercise of the Public Warrants and no conversion of the Series A Preferred Stock or exercise of the Private Warrants.

    The Public Warrants held by the RTW Funds are subject to a Blocker, which is currently set at 4.99% and can be increased to 9.99% upon 61 days’ prior notice and accordingly, the Reporting Persons have included the Shares issuable upon exercise of Public Warrants as if the Blocker was set to 9.99%.

     

    CUSIP No. 02008G10213D/APage 4 of 5 Pages

    The following constitutes Amendment No. 3 (“Amendment No. 3”) to the initial statement on Schedule 13D, filed on August 11, 2023 (the “Initial Schedule 13D”), as amended by Amendment No. 1 filed by the undersigned with the Securities and Exchange Commission on April 17, 2024 (“Amendment No.1”) and Amendment No. 2 filed by the undersigned with the Securities and Exchange Commission on July 2, 2024 (“Amendment No. 2”). This Amendment No. 3 amends the Schedule 13D as specifically set forth herein (the Initial Schedule 13D as amended by Amendment No. 1, Amendment No. 2 and this Amendment No. 3, the “Schedule 13D”). Capitalized terms used in this Amendment No. 3 and not otherwise defined herein have the meanings given to them in the Schedule 13D.

    Item 4. Purpose of Transaction.

    Item 4 of the Schedule 13D is hereby amended to add the following:

    On October 22, 2024, certain RTW Funds provided notice to the Company of their election under the RTW Side Letter, as amended, to surrender 749,998 Shares in consideration for the Additional Revenue Interest Financing Agreement, as contemplated in the RTW Side Letter. Those certain RTW Funds provided irrevocable instructions for the surrender of such shares on October 22, 2024. Accordingly, the Shares of the Company beneficially held by the RTW Funds reported herein has been reduced by 749,998 Shares to reflect the surrender of such shares pursuant to the RTW Side Letter.

     Item 5. Interest in Securities of the Issuer.

    Items 5(a)-(c) are hereby amended and restated as follows:

    (a) The aggregate percentage of Shares reported to be beneficially owned by the Reporting Persons is based upon 64,338,421 Shares which is the difference obtained by subtracting (x) the 749,998 Shares surrendered to the Company as reported herein in Item 4 from (x) the 64,369,381 Shares reported to be outstanding as of September 23, 2024, as disclosed in the Company's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on October 7, 2024, and assumes the conversion of the Notes up to the Conversion Cap (as defined in Item 4 of Amendment No. 1) and the exercise of the Public Warrants and no conversion of the Series A Preferred Stock or exercise of the Private Warrants.

    The Public Warrants held by the RTW Funds are subject to a Blocker (as defined in Item 4 of Amendment No. 2), which is currently set at 4.99% and can be increased to 9.99% upon 61 days’ prior notice and accordingly, the Reporting Persons have included the Shares issuable upon exercise of Public Warrants as if the Blocker was set to 9.99%.

    (b) See rows (7) through (10) of the cover page to this Amendment No. 3 for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

    (c) The Reporting Persons did not effect any transactions with respect to the Shares during the past sixty (60) days other than as reported in Item 4.

     

     

    CUSIP No. 02008G10213D/APage 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

      Date: October 24, 2024

    RTW INVESTMENTS, LP  
       
    By:

    /s/ Roderick Wong, M.D.

     
    Name: Roderick Wong, M.D.  
    Title: Managing Partner  
       

    /s/ Roderick Wong, M.D.

     
    RODERICK WONG, M.D.  
         

     

     

    Get the next $ALUR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALUR

    DatePrice TargetRatingAnalyst
    11/14/2024Buy → Neutral
    Chardan Capital Markets
    10/2/2024$2.00Buy
    TD Cowen
    9/6/2024$2.00Buy
    ROTH MKM
    2/9/2024$5.00Buy
    Jefferies
    More analyst ratings

    $ALUR
    SEC Filings

    View All

    SEC Form 424B3 filed by Allurion Technologies Inc.

    424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    8/15/25 6:05:47 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    SEC Form NT 10-Q filed by Allurion Technologies Inc.

    NT 10-Q - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    8/15/25 6:05:29 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Allurion Technologies Inc.

    424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    8/15/25 6:04:50 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    5/21/25 4:15:08 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Director Rtw Investments, Lp converted options into 1,492,539 shares (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    4/17/25 6:36:58 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    4/1/25 4:15:07 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    5/21/25 4:15:08 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    4/1/25 4:15:07 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update

    Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update. Recent Company Highlights and Outlook Announced new strategic direction focused on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry Signed term sheet with strategic partner to enhance manufacturing and distribution capabilities and R&D pipeline, including the potential joint development of a novel, GLP-1 drug-eluting balloon Submitted protocol for prospective, multi-center trial on combination therapy with low-dose GLP-1s and the Allurion Program to achieve weight los

    8/13/25 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

    Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 (646) 960-0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay

    8/7/25 4:05:00 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry

    Signed term sheet with strategic partner to enhance distribution capabilities and R&D pipeline, including the potential joint development of a novel, GLP-1 drug-eluting balloon Submitted protocol to IRBs for approval on prospective, multi-center trial on combination therapy with low-dose GLP-1s and the Allurion Program to achieve weight loss while maintaining muscle mass and increasing GLP-1 adherence Commenced transition to distribution partners with access to physician networks prescribing GLP-1 therapy and equipped to deliver metabolically healthy weight loss PMA application for the Allurion Balloon successfully accepted by FDA for evaluation Preliminary, unaudited second quarter

    8/5/25 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Allurion Technologies downgraded by Chardan Capital Markets

    Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral

    11/14/24 8:29:33 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Allurion Technologies with a new price target

    TD Cowen initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

    10/2/24 7:13:57 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    ROTH MKM initiated coverage on Allurion Technologies with a new price target

    ROTH MKM initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

    9/6/24 7:25:38 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Leadership Updates

    Live Leadership Updates

    View All

    Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

    Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al

    9/3/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

    Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company's international commercial sales and operations functions. "We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expandi

    8/20/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

    Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably. With a 25-year track record in the health

    6/5/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Financials

    Live finance-specific insights

    View All

    Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update

    Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update. Recent Company Highlights and Outlook Announced new strategic direction focused on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry Signed term sheet with strategic partner to enhance manufacturing and distribution capabilities and R&D pipeline, including the potential joint development of a novel, GLP-1 drug-eluting balloon Submitted protocol for prospective, multi-center trial on combination therapy with low-dose GLP-1s and the Allurion Program to achieve weight los

    8/13/25 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

    Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 (646) 960-0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay

    8/7/25 4:05:00 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

    Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent Company Highlights and Outlook Maintaining 2025 revenue guidance of approximately $30 million with a reduction of approximately 50% in operating expenses compared to 2024 First quarter revenue of $5.6 million and operating expenses of $11.4 million, a 37% decrease in operating expenses compared to prior year; adjusted operating expenses of $10.1 million, a 45% decrease compared to prior year Net operating loss of $7.3 million, a 36% reduction compared to prior year; adj

    5/14/25 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

    SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    11/14/24 4:43:43 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

    SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    11/14/24 4:15:52 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Allurion Technologies Inc.

    SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    10/24/24 5:19:39 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care